Top Stocks To Own Right Now

VEON Ltd. (NASDAQ:VEON) was the recipient of a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 19,380,092 shares, a growth of 34.4% from the April 13th total of 14,417,386 shares. Based on an average daily volume of 8,650,525 shares, the days-to-cover ratio is currently 2.2 days.

Shares of VEON stock opened at $2.68 on Friday. The company has a quick ratio of 0.93, a current ratio of 0.95 and a debt-to-equity ratio of 2.64. The company has a market cap of $4.57 billion, a P/E ratio of 44.67 and a beta of 2.15. VEON has a 52 week low of $2.62 and a 52 week high of $2.69.

Get VEON alerts:

VEON (NASDAQ:VEON) last announced its earnings results on Thursday, March 15th. The Wireless communications provider reported ($0.19) EPS for the quarter. The business had revenue of $2.32 billion for the quarter. VEON had a negative net margin of 5.66% and a negative return on equity of 7.68%. equities analysts predict that VEON will post 0.3 earnings per share for the current fiscal year.

Top Stocks To Own Right Now: CoreSite Realty Corporation(COR)

Advisors’ Opinion:

  • [By ]

    In the Lightning Round, Cramer was bullish on Align Technology (ALGN) , Berkshire Hathaway (BRK.A)   (BRK.B) , Criticare Systems Inc.  (CMD) , Thermo Fisher Scientific (TMO) , IAC Interactive (IAC) and CoreSite Realty (COR) .

  • [By Jack Delaney]

    Take CoreSite Realty Corp. (NYSE: COR), for example. The stock price not only climbed 43.66% from 2017 to 2018, but it also pays its shareholders a dividend of $3.92 per share.

  • [By ]

    CoreSite Realty (COR) : “The data centers have been hot, but the REITS have not. I’m a buyer of this stock, not a seller.”

    Hi-Crush Partners (HCLP) : “This sector has gotten way too hot.”

Top Stocks To Own Right Now: Keysight Technologies Inc.(KEYS)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Massachusetts Financial Services Co. MA increased its position in shares of Keysight (NYSE:KEYS) by 1.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,314,931 shares of the scientific and technical instruments company’s stock after acquiring an additional 18,779 shares during the period. Massachusetts Financial Services Co. MA owned about 0.69% of Keysight worth $68,889,000 at the end of the most recent quarter.

  • [By Joseph Griffin]

    Barings LLC raised its position in Keysight (NYSE:KEYS) by 3.2% during the first quarter, HoldingsChannel.com reports. The firm owned 73,271 shares of the scientific and technical instruments company’s stock after buying an additional 2,300 shares during the quarter. Barings LLC’s holdings in Keysight were worth $3,839,000 at the end of the most recent quarter.

  • [By Logan Wallace]

    Lateef Investment Management L.P. lessened its holdings in shares of Keysight (NYSE:KEYS) by 0.9% during the 1st quarter, HoldingsChannel reports. The fund owned 773,439 shares of the scientific and technical instruments company’s stock after selling 7,177 shares during the period. Keysight comprises approximately 5.3% of Lateef Investment Management L.P.’s investment portfolio, making the stock its 6th biggest position. Lateef Investment Management L.P.’s holdings in Keysight were worth $40,520,000 at the end of the most recent reporting period.

  • [By Max Byerly]

    Barings LLC raised its position in Keysight (NYSE:KEYS) by 3.2% during the first quarter, HoldingsChannel.com reports. The firm owned 73,271 shares of the scientific and technical instruments company’s stock after buying an additional 2,300 shares during the quarter. Barings LLC’s holdings in Keysight were worth $3,839,000 at the end of the most recent quarter.

Top Stocks To Own Right Now: Galmed Pharmaceuticals Ltd.(GLMD)

Advisors’ Opinion:

  • [By Shane Hupp]

    Here are some of the media stories that may have effected Accern’s rankings:

    Get Galmed Pharmaceuticals alerts:

    Galmed Pharmaceuticals’ (GLMD) CEO Allen Baharaff on Q1 2018 Results – Earnings Call Transcript (seekingalpha.com) What You Must Know About Galmed Pharmaceuticals Ltds (NASDAQ:GLMD) Market Risks (finance.yahoo.com) Obeticholic Acid Market Analysis, Recent Trends and Regional Growth Forecast by Types, Applications and Economic … (theexpertconsulting.com) oholic Steatohepatitis (NASH) Market 2023: Know Marketing Channel Future Trend, Growth and Price with Future … (theexpertconsulting.com) Umbilical Cord Blood May Offer Early FH Diagnosis (medscape.com)

    A number of equities analysts have recently commented on GLMD shares. ValuEngine lowered shares of Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. Maxim Group set a $14.00 price target on shares of Galmed Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, May 9th. Finally, HC Wainwright lifted their price target on shares of Galmed Pharmaceuticals from $18.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, February 12th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $20.40.